Lopinavir – Page 15 – Communicable Diseases Research

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019

경증에서 중등도의 코로나바이러스 질환 환자의 바이러스 제거 및 임상 개선을 위한 로피나비르-리토나비르 대 하이드록시클로로퀸 2019

Comparative Study

Published on 2021-03-012022-09-11
Journal: The Korean journal of internal medicine [Category] SARS, 치료제,

Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients

IFNβ1과 로피나비르-리토나비르의 병용 요법은 중증 COVID-19 감염 환자의 산소 공급, 생존 및 퇴원을 증가시킵니다.

Article

Published on 2021-03-012022-09-11
Journal: International immunopharmacology [Category] 치료제,

[키워드] age all-cause mortality Analysis antiviral effects caused clinical study Combination Comorbidity conducted control group coronavirus COVID-19 COVID-19 patient COVID-19 patients COVID-19 treatment death rate defined determine dose during treatment Efficacy hospital hospitalized patient IFN-β1-a immunomodulatory in vitro activity in vivo increase infection with SARS-CoV-2 inflammatory cells inhibit Inpatient intensive care interferon interferon beta Interferon beta-1a International Lopinavir Lopinavir-ritonavir Lopinavir/ritonavir mediator Mortality Multivariate analysis Noninvasive ventilation outcome Oxygenation patients died receiving remained required Retrospective study risk of death Ritonavir SARS-CoV-2 Sex shown significantly standard care survival the disease therapy Treatment virus was done
[DOI] 10.1016/j.intimp.2020.107329 PMC 바로가기 [Article Type] Article

Phytochemicals against SARS-CoV as potential drug leads

잠재적 약물 리드로서 SARS-CoV에 대한 파이토케미컬

Article

Published on 2021-03-012022-09-11
Journal: Biomedical journal [Category] SARS, 신약개발,

[키워드] accelerate against SARS-CoV Analysis analyzed antiinflammatory antimalarial drug Antimalarial drugs Antiviral antiviral drug antiviral drugs assays cellular Cluster cluster analysis coronavirus CoV cysteine derivatives develop Developing drug Drug development drugs followed by health emergency Herbal herbal medicine in vitro information Lopinavir LOPINAVIR AND RITONAVIR MERS molecular docking natural natural products Pandemics pharmaceutical industry phytochemical protease reported researcher Ritonavir Safe SARS-CoV-2 SARS-CoV-2 strain Scientific community selected strain systematic review target
[DOI] 10.1016/j.bj.2020.12.002 PMC 바로가기 [Article Type] Article

Exploring existing drugs: proposing potential compounds in the treatment of COVID-19

Research article

Published on 2021-02-262022-10-05
Journal: Heliyon [Category] 신약개발, 유전자 메커니즘, 치료법, 치료제,

[키워드] ACE2 addressed alignment approved basic candidate characterized Compound confirmed case conserved conserved region COVID-19 COVID-19 epidemic COVID-19 situation database death docking drug Drug repurposing drugs effective evolutionary relationship identify in vitro in vivo inhibit International Johns Hopkins University Lopinavir microorganism Molecular modeling molecular target much higher Off Pacritinib Phylogenetic tree public health emergency Region Remdesivir reported researcher Safe safety profile SARS-CoV-2 SARS-COV-2 infection searched Seven similarity South Asian strain TMPRSS2 Treatment virus viruses was used were used World Health Organization
[DOI] 10.1016/j.heliyon.2021.e06284 [Article Type] Research article

From SARS-CoV-2 hematogenous spreading to endothelial dysfunction: clinical-histopathological study of cutaneous signs of COVID-19

SARS-CoV-2 혈행성 확산에서 내피 기능 장애까지: COVID-19의 피부 징후에 대한 임상-조직병리학적 연구

Case Reports

Published on 2021-02-252022-09-11
Journal: Diagnostic Pathology [Category] MERS, 치료기술,

[키워드] Activation Arterioles Atypical Atypical pneumonia Azithromycin Capillaries capillary Case report caused Chest Chest CT Coagulopathy conducted correlation COVID-19 Cytokines dermatitis died disorder Disruption edema edematous endothelial Endothelial cell endothelial cells Endothelial dysfunction endothelial integrity Endothelial swelling ENhance erythematous erythroderma expression extravasation granulocyte Ground-glass opacities healing hematogenous histological Histopathology Hospitalized Hydroxychloroquine immune system impairment inflammatory cell inflammatory cells initiated Injury intensive care unit Intubated Lopinavir Lopinavir-ritonavir lung microvascular permeability Morphological Nasopharyngeal swab Neck non-specific papillary dermis Patient perivascular Pneumonia positive Rash respiratory respiratory symptom respiratory symptoms Reticular dermis Ritonavir SARS-CoV-2 SARS-COV-2 infection Seven skin spongiosis swelling tested Tocilizumab transferred treated trunk upper limbs vascular abnormalities Viral with COVID-19
[DOI] 10.1186/s13000-021-01075-6 PMC 바로가기 [Article Type] Case Reports

Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial

중등도에서 중증의 COVID-19 치료에서 유전적으로 조작된 인터페론-알파 대 전통적인 인터페론-알파의 효과: 무작위 임상 시험

Randomized Controlled Trial

Published on 2021-02-232022-08-09
Journal: Annals of Medicine [Category] 임상, 치료제,

[키워드] 1:1 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus adaptive immune responses added Adverse adverse events Alpha antiviral agent Antiviral agents antiviral therapy ARMS assigned baseline antiviral agent baseline antiviral agents Clinical efficacy Clinical improvement clinical trial coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 death Effect effective therapy Effectiveness Endpoint event groups head immune responses interferon Interferon alpha interferon-alpha interferon-alpha group interferon-alpha nebulization Lopinavir Lopinavir–ritonavir lopinavir–ritonavir or umifenovir Middle East Middle East respiratory syndrome Coronavirus moderate-to-severe COVID-19 multicenter Negative conversion nucleic acid outbreak pandemic participant Patient patients hospitalized primary endpoint radiological improvement randomised Randomized recombinant super-compound interferon respiratory respiratory syndrome coronavirus Result Ritonavir rSIFN-co rSIFN-co group rSIFN-co nebulization rSIFN-co therapy SARS CoV-2 secondary Secondary endpoints severe acute respiratory syndrome Coronavirus shown traditional interferon-alpha Treatment Trial umifenovir virus nucleic acid
[DOI] 10.1080/07853890.2021.1890329 PMC 바로가기 [Article Type] Randomized Controlled Trial

Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial

COVID-19 환자에서 고용량 비타민 C의 안전성과 효과: 무작위 공개 임상 시험

Randomized Controlled Trial

Published on 2021-02-112022-08-13
Journal: European Journal of Medical Research [Category] 임상, 치료제,

[키워드] 2019-nCoV added addition age and gender antioxidant body temperature boosting immunity clinical trial conducted control group Controlled trial COVID-19 COVID-19 disease COVID-19 infection discharge effective Effectiveness Efficacy function HDIVC High-dose high-dose intravenous vitamin C High-dose vitamin C Hospitalization Hydroxychloroquine ICU intensive care intensive care unit intravenous IRCT20200411047025N1 Laboratory results Lopinavir Lopinavir/ritonavir median Mortality no significant difference Open-label outcome oxygen oxygen saturation Patient patients peripheral Peripheral capillary oxygen saturations Pneumonia Randomized receiving regimen regimens Result Ritonavir Safety SARS-CoV-2 severe COVID-19 disease Severe COVID-19 Infection significantly significantly lower statistically significant difference treated treatment group treatment regimen Trial registration two group two groups underlying diseases Vitamin Vitamin C water-soluble nutrient
[DOI] 10.1186/s40001-021-00490-1 PMC 바로가기 [Article Type] Randomized Controlled Trial

Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results

Covid-19에 대한 용도 변경 항바이러스 약물 - WHO 연대 실험 잠정 결과

Randomized Controlled Trial

Published on 2021-02-112022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 치료제,

[키워드] (rate ratio 28-day mortality 95% CI 95% confidence interval adherence age Analysis antiviral drug antiviral drugs assigned calculated Care coronavirus disease Coronavirus disease 2019 death drug drug regimen examined FIVE group Health Organization hospital Hospital stay Hospitalization hospitalized patient hospitalized patients Hydroxychloroquine in-hospital mortality indicated Inpatient Inpatients intention-to-treat interferon interferon beta Interferon beta-1a Interim interquartile range ISRCTN registry Kaplan-Meier Local Lopinavir mechanical ventilation median Mortality no effect occurred open overall mortality Pairwise comparison Patient patients hospitalized randomization Randomly rate ratio rate ratios receive receiving reduced regimen Remdesivir reported Result Solidarity trial Standard of care status Stratification the patient Treatment Trial Ventilation WHO World Health Organization
[DOI] 10.1056/NEJMoa2023184 PMC 바로가기 [Article Type] Randomized Controlled Trial

COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review

COVID-19: 분자 병태생리학, 유전적 진화 및 전향적 치료법—검토

Review

Published on 2021-02-082022-08-31
Journal: Archives of Microbiology [Category] 신약개발, 치료제,

[키워드] Chloroquine clinical trial contagious continuous monitoring convalescent plasma treatment COVID-19 COVID-19 pandemic Dexamethasone disease drug Drug discovery Drug repositioning/repurposing drug target effective Evolution Favipiravir form Genetic genomic globe had no Hydroxychloroquine life-threatening Lopinavir Lopinavir-ritonavir medical emergency molecular molecular evolution Molecular targets mortality rate no effect pandemic pathophysiology Patient Phylogenetic analysis recent recent finding recent findings recording reduce mortality reducing Remdesivir Ribavarin ribavirin Ritonavir severe forms of COVID-19 shown Side effects specific treatment Spread therapeutic therapeutic option Treatment Trial Viral
[DOI] 10.1007/s00203-021-02183-z PMC 바로가기 [Article Type] Review

Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients

클로로퀸과 로피나비르/리토나비르는 모두 COVID-19 치료에 효과가 없으며 병용하면 병리학이 악화됩니다: 중증 환자를 대상으로 한 단일 센터 경험

Research Article

Published on 2021-02-062022-09-10
Journal: BioMed Research International [Category] 치료제,

[키워드] Administered antimalarial drug Antimalarial drugs Antiviral antiviral drugs C-reactive protein carried Chloroquine circulating Combined Comorbidities Complete COVID-19 COVID-19 therapeutics CRP D-dimer decrease dimer drug Effectiveness ENhance experience ferritin ferritin levels Hospitalization Ill Ineffective knowledge Lactate lactate dehydrogenase LDH leukocytes Lopinavir Lopinavir/ritonavir Lymphocytes Mortality neutrophil off-label off-label use parameters Patient reduce researcher Ritonavir Safe SARS-CoV-2 severely ill patient severely ill patients standard treatment therapeutic option therapeutic options treat treating COVID-19 Treatment
[DOI] 10.1155/2021/8821318 PMC 바로가기 [Article Type] Research Article